Laoukili, Jamila
Constantinides, Alexander
Wassenaar, Emma C. E.
Elias, Sjoerd G.
Raats, Danielle A. E.
van Schelven, Susanne J.
van Wettum, Jonathan
Volckmann, Richard
Koster, Jan
Huitema, Alwin D. R.
Nienhuijs, Simon W.
de Hingh, Ignace H. J. T.
Wiezer, René J.
van Grevenstein, Helma M. U.
Rinkes, Inne H. M. Borel
Boerma, Djamila
Kranenburg, Onno http://orcid.org/0000-0002-2112-4390
Funding for this research was provided by:
KWF Kankerbestrijding (KWF2015-8088)
Article History
Received: 1 September 2021
Revised: 19 January 2022
Accepted: 3 February 2022
First Online: 22 February 2022
Ethics approval and consent to participate
: All patients provided informed consent to their tumour tissues being used for either molecular and genetic analysis, and/or PMDO generation. PDMO samples have been collected with patient consent as part of the CRC-PIPAC study (Netherlands Trial Register NL6426/NTR6603) and has been approved by the Medical Review Ethics Committee (NL60405.100.17). The study was performed in accordance with the Declaration of Helsinki.
: Not applicable.
: The authors declare no competing interests.